CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that management will
present at two upcoming investor conferences:
-
Stephens Fall Investor Conference at the Lotte New York Palace Hotel
in New York City on November 7, 2017 at 2:00 PM ET. Kevin D. Green,
vice president, finance and chief financial officer, will present for
Cerus.
-
Canaccord Genuity Medical Technologies & Diagnostics Forum at the
Westin Grand Central in New York City on November 9, 2017 at 2:30 PM
ET. Dr. Laurence M. Corash, co-founder and chief scientific officer,
will present for Cerus.
A live webcast of the presentations will be available on the Investor
Relations page of the Cerus web site at http://www.cerus.com/ir.
A replay will be available for approximately two weeks following the
completion of the event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171031005505/en/
Source: Cerus Corporation